HomeVatican Radio
Vatican Radio   
more languages  

     Home > Culture & Society  >  2013-10-08 18:02:23
A+ A- print this page

Vaccine against Malaria ready, says GlaxoSmithKline

A British drug pharmaceutical company known GlaxoSmithKline said on Monday that it was seeking Regulatory approval for its malaria vaccine after trial data showed that it had reduced malaria infections in African children. The vaccine was tested on 15,500 children in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The researchers told reporters in South Africa that the vaccine is known as RTS,S. The trials showed that 18 months after vaccination, children aged between five and 17 months had a 46% reduction in the risk of clinical malaria compared to unvaccinated children. But in infants aged between six and 12 weeks at the time of vaccination, there was only a 27% reduction in the risk of catching the disease. The trials began in 2009. Malaria is caused by protozoan parasites and is spread from one person to another by a female anopheles mosquito. It is the leading killer disease in Africa.


About us Schedules Contacts VR Productions Links Other languages Holy See Vatican State Papal liturgies
All the contents on this site are copyrighted ©. Webmaster / Credits / Legal conditions / Advertising